-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：我們下調目標價15美元至150美元，採用更為合理的股權風險溢價，但仍能反映APO超過20%的強勁手續費收入增長和穩健的資產管理規模增長。我們的目標價對應的預期本益比為16.6倍，而過去三年的平均預期本益比為16.3倍。我們先前對每股盈餘(EPS)的預期過於樂觀，因此將2026年和2027年的EPS預期分別下調0.50美元至9.00美元和0.70美元至10.75美元，這兩個下調幅度均接近市場普遍預期，對應的預期營收分別為53億美元和63億美元。我們評級面臨的風險是股價波動，主要受低品質直接貸款或私募股權投資可能因人工智慧對軟體公司的潛在顛覆而受到衝擊的擔憂影響。在財報電話會議上，APO表示，受人工智慧對科技公司衝擊的低品質直接貸款（非投資等級）對總資產管理規模的影響不大。在10,260億美元的總資產管理規模中，信貸業務佔8,340億美元（佔總數的81%），股票業務佔1,920億美元（佔19%）。 APO預計2026年手續費收入佔比將超過20%，其中75%的收入來自成熟的信貸業務，25%來自股票業務。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL